Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from SanBio Co ( (JP:4592) ) is now available.
SanBio Co., Ltd. has entered into a contract manufacturing agreement with JCR Pharmaceuticals for the trial production of AKUUGO® Suspension for Intracranial Implantation. This collaboration aims to explore future manufacturing opportunities to ensure stable production and diversify supply, particularly as SanBio seeks market expansion into the US and additional indications such as ischemic stroke. The agreement is expected to have minimal impact on the current fiscal year’s financial performance.
More about SanBio Co
SanBio Co., Ltd., founded in California in 2001, is a leader in regenerative medicine, focusing on the research, development, manufacturing, and sale of regenerative cell therapies. The company emphasizes treating central nervous system disorders with unmet medical needs. Its primary product, AKUUGO®, is approved for improving chronic motor paralysis related to traumatic brain injury.
YTD Price Performance: 0.0%
Average Trading Volume: 1,635
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $346.1M
For an in-depth examination of 4592 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue